Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serum Institute of India Ltd.

www.seruminstitute.com

Latest From Serum Institute of India Ltd.

China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.

Coronavirus COVID-19 China

India's Serum Joins Oxford Efforts To Expedite COVID-19 Vaccine

After partnering with Merck KGaA and Cobra Biologics, Oxford University has now tied up with Serum Institute of India to manufacture its COVID-19 vaccine and a marketing pact is likely. With clinical trials of the ChAdOx1 nCoV-19 vaccine underway, Serum intends to set aside other COVID-19 vaccine development plans for the time being.

Coronavirus COVID-19 Commercial

Coronavirus TV: Vaccine Expertise And R&D In India

Vibha Ravi, the Mumbai-based subeditor within Scrip's APAC content team, talks about how Indian firms are stepping up to the challenge of developing a coronavirus vaccine in this episode of Pharma Intelligence's Coronavirus TV.

Vaccines India

With Interferon, Zydus Cadila Launches Third Salvo Against COVID-19

Cadila Healthcare is evaluating the use of pegylated interferon alpha-2b to treat COVID-19 and will explore the possibility of approval in the US under the compassionate use program. This marks the company’s third front to fight the disease after hydroxychloroquine and a vaccine.

Coronavirus COVID-19 Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Serum Institute of India Ltd.
  • Senior Management
  • Adar C Poonawalla, CEO
  • Contact Info
  • Serum Institute of India Ltd.
    Phone: (91) 202 699 3900
    212/2, Hadapsar, Off Soli Poonawalla Rd.
    Pune, 411028
    India
UsernamePublicRestriction

Register